CMV Reactivation and CMV-Specific Cell-Mediated Immunity after Chimeric Antigen Receptor T-Cell Therapy.

Eleftheria KampouriSarah S IbrahimiHu XieElizabeth R WongJessica B HechtMandeep K SekhonAlythia VoTerry L Stevens-AyersDamian J GreenJordan GauthierDavid G MaloneyAilyn PerezKeith R JeromeWendy M LeisenringMichael J BoeckhJoshua A Hill

Published in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023)

CMV testing could be considered between 2-6 weeks in high-risk CARTx-recipients.

Keyphrases

cell therapy
stem cells
mesenchymal stem cells
single cell
kidney transplantation